Citadel Advisors
AVIR icon

Citadel Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

Citadel Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$115K Buy
+21,400
New +$98.3K ﹤0.01% 11894
2025
Q4 		– Sell
-31,100
Closed -$90.2K – 12641
2025
Q3 		$90.2K Buy
+31,100
New +$106K ﹤0.01% 11908
2025
Q2 		– Sell
-3,400
Closed -$10.2K – 12491
2025
Q1 		$10.2K Sell
3,400
-4,200
-55% -$13.1K ﹤0.01% 13552
2024
Q4 		$25.5K Buy
7,600
+6,700
+744% +$22.3K ﹤0.01% 13013
2024
Q3 		$3.02K Sell
900
-1,900
-68% -$6.89K ﹤0.01% 13695
2024
Q2 		$9.27K Sell
2,800
-10,300
-79% -$38.4K ﹤0.01% 13147
2024
Q1 		$52.9K Sell
13,100
-900
-6% -$3.52K ﹤0.01% 12128
2023
Q4 		$42.7K Sell
14,000
-1,600
-10% -$4.84K ﹤0.01% 11954
2023
Q3 		$46.8K Sell
15,600
-200
-1% -$680 ﹤0.01% 11832
2023
Q2 		$59.1K Sell
15,800
-7,400
-32% -$27.7K ﹤0.01% 11607
2023
Q1 		$77.7K Sell
23,200
-46,200
-67% -$187K ﹤0.01% 11601
2022
Q4 		$334K Sell
69,400
-131,300
-65% -$664K ﹤0.01% 9081
2022
Q3 		$1.14M Sell
200,700
-7,100
-3% -$54.3K ﹤0.01% 6701
2022
Q2 		$1.48M Buy
207,800
+80,300
+63% +$548K ﹤0.01% 6162
2022
Q1 		$921K Sell
127,500
-32,000
-20% -$217K ﹤0.01% 7900
2021
Q4 		$1.43M Buy
159,500
+71,600
+81% +$1.12M ﹤0.01% 7002
2021
Q3 		$3.08M Buy
87,900
+51,200
+140% +$1.42M ﹤0.01% 5290
2021
Q2 		$788K Buy
36,700
+31,900
+665% +$958K ﹤0.01% 8981
2021
Q1 		$296K Buy
+4,800
New +$324K ﹤0.01% 10885

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors's AVIR Position: Q1 2026 in Review

Citadel Advisors increased its Atea Pharmaceuticals (AVIR) stake by 13% in Q1 2026, buying an estimated $26.2K and bringing the position to 48,401 shares worth $260K. The position accounts for ﹤0.01% of the portfolio, ranked #10798.

Citadel Advisors first reported a position in AVIR in Q4 2020 and has held it in 21 quarters since. The position peaked at $14.9M in Q4 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Citadel Advisors held 48,401 shares of Atea Pharmaceuticals worth $260K as of Q1 2026.
  • Citadel Advisors bought 5,710 Atea Pharmaceuticals shares in Q1 2026, an estimated $26.2K.
  • Atea Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10798 holding.
  • Citadel Advisors first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 21 quarters since.
  • Citadel Advisors's Atea Pharmaceuticals position peaked at $14.9M in Q4 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.